|
|
 | | | |
- close
- close
- close
- close
| |||||||||
This excerpt taken from the ELN 20-F filed Feb 28, 2007. (D) Divested
products
During 2004, we sold a number of products and businesses as part
of the recovery plan, which commenced in July 2002 and was
completed in early 2004, and our subsequent strategic
repositioning as a biotechnology company focused on a number of
key therapeutic markets. The decrease in revenue from divested
products in 2005 was primarily due to the divestment of a number
of products and businesses during 2004, principally the European
business and Zonegran, which are described below. No divestments
occurred in 2005.
In February 2004, we completed the sale of our European sales
and marketing business to Zeneus. Revenue for the divested
European business was $Nil for 2005 (2004: $10.5 million).
In April 2004, we sold our interests in Zonegran for North
America and Europe to Eisai. Zonegran generated revenue of $Nil
for 2005 (2004: $41.2 million).
Table of Contents
This excerpt taken from the ELN 20-F filed Mar 30, 2006. (D) Divested
products
During 2003 and 2004, we sold a number of products and
businesses as part of the recovery plan, and our subsequent
strategic repositioning as a biotechnology company focused on a
number of key therapeutic markets. The decrease in product
revenue in 2004 was primarily due to the divestment of a number
of products and businesses during 2003 and 2004, principally the
European business, Zonegran, Skelaxin and Sonata, which are
described below.
In February 2004, we completed the sale of our European sales
and marketing business to Zeneus. Revenue for the divested
European business was $10.5 million for 2004 (2003:
$89.0 million).
In April 2004, we sold our interests in Zonegran for North
America and Europe to Eisai. Zonegran generated revenue of
$41.2 million for 2004 (2003: $80.7 million).
In June 2003, we completed the sale of our primary care
franchise, principally our rights to Skelaxin and Sonata, to
King. We did not report any product revenue from sales by us of
Skelaxin and Sonata during 2004
(2003: $108.4 million). Following divestment, we earn
royalties on sales of Skelaxin by King. This amounted to
$12.2 million in 2004 (2003: $7.4 million).
Table of Contents
| EXCERPTS ON THIS PAGE:
RELATED TOPICS for ELN: |
| |||||||
